- In December 2024, Roche unveiled its cobas Mass Spec solution after receiving the Conformité Européenne (CE) mark approval, marking a significant step in the global launch of the product. The cobas Mass Spec solution includes the cobas i 601 analyzer and the Ionify reagent pack, which features four assays for steroid hormones. The launch is expected to enhance the accessibility and efficiency of mass spectrometry in clinical settings, potentially driving growth in the market by enabling more widespread use of advanced diagnostic tools in routine laboratory practices
- In June 2024, Thermo Fisher Scientific introduced a new mass spectrometry platform, alongside several updates to its existing products, at the American Society for Mass Spectrometry (ASMS) conference held in Anaheim, California. This release is expected to enhance the company’s position in the mass spectrometry market by offering improved performance, innovative features, and more advanced capabilities for a wide range of applications, further driving adoption and growth in various industries such as pharmaceuticals, healthcare, and research
- In October 2020, Shimadzu expanded its operations by opening a branch office in Copenhagen, Denmark. This move allowed the company to better serve the Nordic region with its full range of analytical instrumentation solutions, such as mass spectrometry and chromatography. The expansion strengthened Shimadzu’s presence in Europe, offering closer support to local customers in industries such as pharmaceuticals, healthcare, and environmental testing
- In April 2020, MAP Sciences, a UK-based diagnostics firm, developed a rapid test for COVID-19. The test provided quicker, more accurate results than traditional methods, addressing the urgent need for reliable diagnostics during the pandemic. This innovation played a key role in accelerating testing efforts and highlighted MAP Sciences’ expertise in delivering advanced diagnostic solutions
